Research programme: anticancer nanotherapeutics - Immune Pharmaceuticals

Drug Profile

Research programme: anticancer nanotherapeutics - Immune Pharmaceuticals

Alternative Names: Anti-EGFR NanomAbs; Anti-H-ferritin NanomAbs; Anti-HER2 NanomAbs; Antibody nanoparticle conjugates - Immune Pharmaceuticals; Monoclonal antibody-nanomedicine conjugates - Immune Pharmaceuticals; Nano-therapeutics - Immune Pharmaceuticals; NanomAbs®

Latest Information Update: 21 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Pharmaceuticals
  • Developer Immune Pharmaceuticals Ltd
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 May 2015 Preclinical trials in Cancer in Israel (unspecified route) before May 2015 (Immune Pharmaceuticals pipeline)
  • 26 Aug 2013 Immune Pharmaceuticals Ltd has merged with EpiCept Corp to form Immune Pharmaceuticals Inc
  • 23 May 2012 Early research in Cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top